Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors

31 Aug 2022

Abstract excerpt

Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10-15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, clinical characteristics, and treatment response compared to tumors with receptor tyrosine kinase protein (KIT) mutations (60-70%). Many clinical studies have investigated the use of tyrosine kinase inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Tumor Research and Treatment
Share to Neurofibromatosis and Schwannoma Cases
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36119525
DOI: 10.3389/fonc.2022.927587

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumorsPMID 36119525Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.Semantic proximity Read ↗

Gastrointestinal stromal tumor: a review of current and emerging therapies.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

[Clinicopathological analysis of gastrointestinal stromal tumors with PDGFRA mutations].Semantic proximity Read ↗

New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategiesSemantic proximity Read ↗

New targets and therapies for gastrointestinal stromal tumors.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.